Cell line (origin) protocol passage before transplant site of transplant transplanted cells mouse strain: sex:
age: condition
histology after -3 months histology after 6- months pathological diagnosis
Human fetal frontal lobe (9 weeks old) oh-NSC-7-fb p13 Striatum, bilateral 2x10^6/mouse NOG mouse : female :
9 weeks old : intact
#1
#2
#3
#4
#5
#6
pathological
diagnosis
Human fetal frontal lobe (9 weeks old) oh-NSC-7-fb p13 Spinal cord, epicenter of injury 1x10^5/mouse NOD/SCID mouse : female :
9 weeks old : SCI9pod
#b4
#r1
#r2
#r4
#r5
#r6
pathological
diagnosis
Human fetal hindbrain (5-7 weeks old) SAI-1 p27 Striatum, bilateral 2x10^6/mouse NOG mouse : female :
9 weeks old : intact
#1
#2
#3
pathological
diagnosis
Human fetal hindbrain (5-7 weeks old) SAI-1 p28 Spinal cord, epicenter of injury 1x10^5/mouse NOD/SCID mouse : female :
9 weeks old : SCI9pod
#r1
#r3
#r4
pathological
diagnosis
Human adult PBMC-derivediPSC (1201C1) NR-NSPC p12 Striatum, bilateral 2x10^6/mouse NOG mouse : female :
9 weeks old : intact
#1
#2
#3
#5
#6
#4
pathological
diagnosis
Human adult PBMC-derivediPSC (1201C1) NR-NSPC p12 Spinal cord, epicenter of injury 1x10^5/mouse NOD/SCID mouse : female :
9 weeks old : SCI9pod
#b10
#b2
#b4
#b7
#r2
#r6
pathological
diagnosis
Human adult PBMC-derivediPSC (1231A3) EB-NSPC p7 Striatum, bilateral 2x10^6/mouse NOG mouse : female :
9 weeks old : intact
#1
#2
#3
#4
#5
#6
pathological
diagnosis
Human adult PBMC-derivediPSC (1231A3) EB-NSPC p7 Spinal cord, epicenter of injury 1x10^5/mouse NOD/SCID mouse : female :
9 weeks old : SCI9pod
#b2
#b4
#r1
#b6
#r3
pathological
diagnosis
Human adult dermal fibroblast-dericed iPSC lt-NESC AF22 p37 Striatum, bilateral 2x10^6/mouse NOG mouse : female :
9 weeks old : intact
#4
#5
#6
pathological
diagnosis
Human adult PBMC-derivediPSC (1201C1) EB-NSPC p8 Spinal cord, epicenter of injury 1x10^5/mouse NOD/SCID mouse : female :
9 weeks old : SCI9pod
#b6
#r10
#r6
pathological
diagnosis
Human adult dermal fibroblast-dericed iPSC lt-NESC AF22 p37 Spinal cord, epicenter of injury 1x10^5/mouse NOD/SCID mouse : female :
9 weeks old : SCI9pod
#b6
#b7
#b8
pathological
diagnosis
Human adult PBMC-derivediPSC (1201C1) EB-NSPC p8 Striatum, bilateral 2x10^6/mouse NOG mouse : female :
9 weeks old : intact
#1
#2
#3
#4
#5
#6
pathological
diagnosis
Human adult PBMC-derivediPSC (1210B2) lt-NESC (EGF-) p10 Spinal cord, epicenter of injury 1x10^5/mouse NOD/SCID mouse : female :
9 weeks old : SCI9pod
#b2
#b7
#r3
#r4
#r7
pathological
diagnosis
Human adult PBMC-derivediPSC (1210B2) lt-NESC (EGF-) p8 Striatum, bilateral 2x10^6/mouse NOG mouse : female :
9 weeks old : intact
#1
#2
#3
#4
#5
pathological
diagnosis
Human adult PBMC-derivediPSC (1210B2) lt-NESC (EGF-) p20 Striatum, bilateral 2x10^6/mouse NOG mouse : female :
9 weeks old : intact
#1
#2
#3
pathological
diagnosis
Human adult PBMC-derivediPSC (1210B2) lt-NESC (EGF-) p20 Spinal cord, epicenter of injury 1x10^5/mouse NOD/SCID mouse : female :
9 weeks old : SCI9pod
#b7
#r2
#r5
pathological
diagnosis
Human adult PBMC-derivediPSC (1210B2) lt-NESC (EGF+) p7,8 Spinal cord, epicenter of injury 1x10^5/mouse NOD/SCID mouse : female :
9 weeks old : SCI9pod
#b8
#b9
#r1
#r2
#r5
#r9
pathological
diagnosis
Human adult PBMC-derivediPSC (1210B2) lt-NESC (EGF+) p11 Striatum, bilateral 2x10^6/mouse NOG mouse : female :
9 weeks old : intact
#2
#4
#6
#1
#3
#5
pathological
diagnosis
Human adult PBMC-derivediPSC (1210B2) lt-NESC (EGF+) p20 Striatum, bilateral 2x10^6/mouse NOG mouse : female :
9 weeks old : intact
#1
#2
#3
pathological
diagnosis
Human adult PBMC-derivediPSC (1210B2) lt-NESC (EGF+) p20 Spinal cord, epicenter of injury 1x10^5/mouse NOD/SCID mouse : female :
9 weeks old : SCI9pod
#b1
#b10
#b5
pathological
diagnosis
Human adult PBMC-derivediPSC (1210B2) EB-NSPC p8 Striatum, bilateral 1x10^6/mouse NOG mouse : female :
9 weeks old : intact
#2
#3
#5
#1
#4
pathological
diagnosis
Human adult PBMC-derivediPSC (1210B2) EB-NSPC p8 Spinal cord, epicenter of injury 5x10^5/mouse NOD/SCID mouse : female :
9 weeks old : SCI9pod
#1
#3
#7
#5
#9
pathological
diagnosis
Human adult PBMC-derivediPSC (1210B2) NR-NSPC p10 Striatum, bilateral 2x10^6/mouse NOG mouse : female :
9 weeks old : intact
#1
#2
#4
#1
#3
#5
pathological
diagnosis
Human adult PBMC-derivediPSC (1210B2) NR-NSPC p10 Spinal cord, epicenter of injury 5x10^5/mouse NOD/SCID mouse : female :
9 weeks old : SCI9pod
#6
#8
#1
#10
pathological
diagnosis
Human adult PBMC-derivediPSC (1231A3) NR-NSPC p10 Striatum, bilateral 1x10^5/mouse NOG mouse : female :
9 weeks old : intact
#1
#2
#3
#4
#5
#6
pathological
diagnosis
Human adult PBMC-derivediPSC (1231A3) NR-NSPC p10 Spinal cord, epicenter of injury 1.4x10^6/mouse NOD/SCID mouse : female :
9 weeks old : SCI9pod
#b3
#b5
#b6
#r4
#r5
#r7
pathological
diagnosis
Mouse fetal NSPC (ffLuc+) Transgenic mice cp156-derived, GFP+ p3 Striatum, bilateral 2x10^6/mouse B6J : female :
9 weeks old : 9days after SCI
#2
#3
#4
#5
pathological
diagnosis
Human adult dermal fibroblast-dericed iPSC lt-NESC AF22 p54 Striatum, bilateral 2x10^6/mouse NOG : female :
10 weeks old : intact
#1
#3
#2
#5
pathological
diagnosis
Human adult dermal fibroblast-dericed iPSC lt-NESC AF22 p55 Striatum, bilateral 2x10^6/mouse NOG : female :
9 weeks old : intact
#2
#4
pathological
diagnosis
Human adult dermal fibroblast-dericed iPSC (409B2) lt-NESC p24 Striatum, bilateral 2x10^6/mouse NOG : female :
9 weeks old : intact
#1
#2
#3
#4
#5
pathological
diagnosis

*NSPC: neural stem/progenitor cells
*SCI: spinal cord injury (contusion injury, 60-70kdn by IH impacter)
*PBMC: peropheral blood derived mononuclear cell
*oh-NSC-7-fb: Kanemura et al, Journal of Neuroscience Research, 2002
*SAI-1: Tailor et al, Journal of Neuroscience, 2013
*AF22: Falk et al, Plos ONE, 2012

Sugai K, Fukuzawa R, Shofuda T, Fukusumi H, Kawabata S, Nishiyama Y, Kawai K, Isoda M, Kanematsu D, Hashimoto-Tamaoki T, Kohyama J, Iwanami A, Suemizu H, Ikeda E, Matsumoto M, Kanemura Y, Nakamura M, Hideyuki O. Pathological classification of human iPSC-derived neural stem/progenitor cells towards safety assessment of transplantation therapy for CNS diseases. Molecular Brain. 2016 Sep 19;9(1):85. doi: 10.1186/s13041-016-0265-8. [PubMed]


Isoda M, Kohyama J, Iwanami A, Sanosaka T, Sugai K, Yamaguchi R, Matsumoto T, Nakamura M, Okano H. Robust production of human neural cells by establishing neuroepithelial-like stem cells from peripheral blood mononuclear cell-derived feeder-free iPSCs under xeno-free conditions. Neurosci Res. 2016 Sep;110:18-28. doi: 10.1016/j.neures.2016.04.003. Epub 2016 Apr 13. [PubMed]

ご利用条件

iPSC-NSPC(「本サイト」)のコンテンツは、以下に定める条件(「本ご利用条件」)に従ってご利用いただくことを条件とし、国立研究開発法人日本医療研究開発機構 (Japan Agency for Medical Research and Development (AMED))、および再生医療実現拠点ネットワーク事業 拠点Aとして慶應義塾大学整形外科学教室および生理学教室が取得したデータを、厚生労働省ヒト幹細胞情報化推進事業などが慶應義塾(「慶應」)を通じて提供するものです。

利用者が本サイトにアクセスしてこれを利用した場合は、本ご利用条件に同意したものとみなされます。
本サイトにおけるリンクが提供された第三者のウエブサイトは、利用者の便宜のためのものでありますが、あくまで第三者が運営するもので、その内容について慶應は関知せず、またいかなる責任も負いません。


サイトポリシー

幹細胞および幹細胞研究に資する細胞を用いた再生医療研究、とくに動物モデルへの移植実験の結果を集約し、研究者間の情報交換および共同研究の促進を図るとともに、一般市民に対して幹細胞に関する情報を提供することで、社会的な理解を増進し、幹細胞を用いた再生医療研究を活性化することを目的に、厚生労働省ヒト幹細胞情報化推進事業などの一環として、学校法人慶應義塾生理学教室および整形外科学教室が運営しております。

コンテンツの利用

iPSC-NSPCに含まれるコンテンツの著作権その他知的財産権は、慶応義塾大学に帰属します。
またコンテンツは、営利目的を除き、転載・リンクすることができます。使用する場合は、使用先のテキスト、図版、画像、映像などに当ウェブサイトのURL、もしくは該当情報の原著論文(Sugai et al., Molecular Brain, 2016)を記載していただくようお願いいたします。

免責事項

1.iPSC-NSPCの情報を利用することにより利用者に損害が生じたとしても、責任を負いません。
2.利用者に対して事前の予告なしに情報を変更あるいは削除し、あるいは運用を中断または中止することがあります。

当該変更若しくは削除、または中断、中止等によって、万一利用者に損害が生じたとしても、慶應は責任を負いません。

お問い合わせ

ご意見・お問い合わせフォームよりご連絡ください。


助成元クレジット

This work was supported in part by grants from the Japan Science and
Technology (JST)-California Institute for Regenerative Medicine (CIRM)
Collaborative Program; Grants-in-Aid for Scientific Research from the Japan
Society for the Promotion of Science (SPS) and the Ministry of Education,
Culture, Sports, Science and Technology of Japan (MEXT); and a grant from
the Research Center Network for Realization of Regenerative Medicine from
JST and Japan Agency for Medical Research and Development (AMED) (to H.O.,
M.N. and Y.K.).  H.O. is a paid scientific consultant for San Bio, Co.,
Ltd. All other authors declare that they have no competing financial interests.

上記とあわせてSKIPのサイトポリシーもご覧ください。